Indeed, DNA hypermethylation of numerous genes, including the tumor suppressor genes RASSF1A and TIMP3, has been identified in the urine of patients with urogenital schistosomiasis [9] . Other investigators have identified DNA methylation of RARbeta2 and APC as potential urine biomarkers of bladder cancer, with schistosomiasis-associated cases having higher rates of methylation of these genes [10] . Yet another group reported differential methylation of CDH1, DAPK1, CDKN2A, MGMT, ICDKN2B, FHIT, APC, RASSF1, GSTP1, RARB, and TP73 in bladder cancer specimens, with schistosomiasis-associated specimens featuring more differentially methylated genes than those not associated with this infection [11] . Interestingly, Saad et al. reported that levels of N7-methylguanine, a form of methylated guanine, were more frequently elevated in cancerous versus normal bladder tissues from patients with bladder cancer, regardless of whether it was associated with schistosomiasis or not [12] . However, this marker was not further increased in the subset of patients with schistosomal bladder cancer (relative to non-schistosomiasis-associated cancers), suggesting that DNA methylation is not unique to schistosomal bladder cancer. Regardless, hypermethylation of genes (especially tumor suppressor genes) may be a key cause of reversible preneoplastic lesions of the bladder urothelium exposed to S. haematobium infection.
Despite the importance of S. haematobium as a bladder carcinogen, studies of the associated basic cancer biology (including the role of DNA methylation) have been limited because of a historical lack of tractable animal models for urogenital schistosomiasis. To address the need for tractable tools to study schistosomal cancer biology, we developed the first experimentally tractable mouse model of urogenital schistosomiasis [13] . In this model, microinjection of S. haematobium parasite eggs into the bladder walls of mice leads to rapid urothelial hyperplasia [13] and squamous metaplasia. Indeed, urothelial hyperplasia persists for at least 3 months after egg exposure [13] . Thus, our approach recapitulates key preneoplastic changes in the bladder associated with urogenital schistosomiasis.
To identify what bladder urothelial DNA methylation events occur in the preneoplastic period in our mouse model of urogenital schistosomiasis, we microinjected S. haematobium eggs into the bladder walls of mice and 2 weeks later microdissected the urothelium of each bladder from the remaining bladder tissue. The granuloma and the detrusor tissue were discarded (S1 Fig) . Granuloma formation was noted in all S. haematobium-injected bladders. We then used reduced representation bisulfite sequencing (RRBS) [14, 15] to profile DNA methylation across the urothelial genome. RRBS focuses on methylation of cytosines within CpG dinucleotide "islands," which are genomic regions enriched for potential DNA methylation sites. In brief, DNA was extracted from each specimen and the restriction enzyme Msp1 used to fragment DNA at CpG islands. After bisulfite treatment samples were fragmented to a length of 175-225 bp, they were then amplified by PCR. Multiplexed sequencing was performed using the Illumina Hi-Seq platform. The output was aligned to the Mouse Genome Reference Consortium Mus musculus genome (GRCm38/mm10) using Bismark software. Methylation analysis was performed with methylKit and the Integrative Genomics Viewer (IGV).
Using thresholds of >10x coverage, >25% difference in methylation, and p < 0.05, we found that short-term exposure of the mammalian bladder to S. haematobium infection led to massive changes in DNA methylation of the urothelium. S. haematobium egg-injected mice featured major alterations in their methylome (versus control mice) 2 weeks post-egg exposure (Fig 1) . 13,333 cytosines were hypermethylated, and 6,244 were hypomethylated. These data were processed using a promoter identification algorithm and subsequently fed into Database for Annotation, Visualization and Integrated Discovery (DAVID) pathways analysis. Of these differentially methylated cytosines, 1,019 were found to be within 1,000 base pairs of a transcription start site for a known gene (i.e., putative promoter regions). Six of these genes are part of the Wnt canonical pathway (Fig 2) , which is related to cell proliferation. A CpG in the promoter of the Wnt inhibitory factor-1 (Wif1) gene, a gene silenced by hypermethylation in bladder tumors and other cancers [16, 17] , was methylated 54% of the time in egg-injected mice, 34% in nitrosamine-fed mice, and 7% in control mice. Thus, even short-term exposure of the mammalian bladder to S. haematobium eggs results in profound alterations in DNA methylation, including in the promoters of known tumor suppressor genes such as Wif1. Indeed, through qPCR we discovered that WIF-1 expression was decreased in mouse urothelia after subepithelial bladder injections with eggs versus control vehicle (0.58-fold expression in six egg-injected mice compared to two control-injected mice, 95% CI 0.475-0.713). Primary sequencing data can be found at http://www.ncbi.nlm.nih.gov/bioproject/PRJNA278470. Given that S. haematobium eggs induced differential methylation of many urothelial genes, we sought to reverse this process pharmacologically. We gave the DNA methylation inhibitor 5-fluoro-2 0 -deoxycytidine (FdCyd, 12.5 mg/kg) and tetrahydrouridine (THU, an inhibitor of FdCyd metabolism, 25 mg/kg) on an every other day basis (14 days total) intraperitoneally to S. haematobium egg-injected mice. This drug combination suppressed S. haematobium egg-induced urothelial hyperplasia, a key preneoplastic change in the bladder (Fig 3) . Specifically, mice treated with FdCyd and THU had a mean urothelial thickness of 67 μm (±19) and those treated with vehicle injections had a mean thickness of 101 μm (±26, p = 0.043-unpaired Student's t test). To our knowledge, this is the first in vivo demonstration that pharmacologic inhibition of DNA methylation can prevent preneoplastic changes in the bladder. Thus, manipulating DNA methylation may be a promising approach to slow or prevent bladder carcinogenesis in highrisk patient populations, namely those with extensive exposure to carcinogens such as urogenital schistosomiasis. Mass drug administration campaigns, snail control, better water hygiene, and public education regarding schistosomiasis are likely to have the greatest impact on bladder cancer associated with S. haematobium. However, a period of chronic bladder inflammation caused by parasite eggs may be enough to predispose individuals to subsequent metaplastic changes, even after successful treatment [18] .
Admittedly, our suggestions are highly speculative, and much more detailed work is required to characterize any mechanistic relationships between urogenital schistosomiasis-induced urothelial DNA methylation and bladder oncogenesis. Nonetheless, there are indications that chronic cystitis and squamous cell carcinoma of the bladder, both linked to urogenital schistosomiasis, may have causal associations with bladder urothelial DNA methylation [19, 20] . If a relationship between S. haematobium infection-mediated bladder urothelial DNA methylation and bladder oncogenesis is confirmed, then we propose that it may be possible to identify S. haematobium-infected or former patients at high risk of bladder carcinogenesis through urine testing for urothelial DNA methylation patterns. Administration of DNA methylation inhibitors such as FdCyd, which are currently in clinical trials for urothelial carcinoma, could then be evaluated for their ability to reduce the risk of these patients developing advanced schistosomal bladder cancer. 
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